Cancer Drug Pipeline Information for Patient … Drug Pipeline Information for Patient Advocacy Groups ... Cancer Drug Pipeline Information for Patient Advocacy Groups ... Xtandi enzalutamide
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Brand Name Generic Name Manufacturer Indication Route of
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Cancer Drug Pipeline Information for Patient Advocacy Groups
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Ibrance palbociclib Pfizer Recurrent advanced breast cancer Oralhttp://www.pfizer.com/sites/default/files/product-
pipeline/PfizerPipeline_1.pdf
Ibrance palbociclib Pfizer High-risk early breast cancer Oralhttp://www.pfizer.com/sites/default/files/product-
pipeline/PfizerPipeline_1.pdf
Ibrance palbociclib Pfizer Early breast cancer in adjuvant setting Oralhttp://www.pfizer.com/sites/default/files/product-
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
ribociclib Novartis Breast cancer Oralhttps://www.novartisoncology.com/about-us/our-
pipeline
SERD (GDC-
0810)Genentech ER+ HER2-ngeative breast cancer Oral http://www.gene.com/medical-professionals/pipeline
TAK-228 Takeda Breast cancer Oralhttps://www.takedaoncology.com/content/assets/Tak
eda-Global-Oncology-Pipeline.pdf
talazoparib PfizerGermline BRCA-mutated metastatic breast
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Gastrointestinal Cancer
abemaciclib Eli Lilly Pancreatic cancer Oralhttp://lillyoncologypipeline.com/molecule/cdk-4-and-
cdk-6-inhibitor/trials
Andecaliximab Gilead Sciences Gastric Cancer Subcutaneous http://www.gilead.com/research/pipeline
avelumab EMD Serono First line gastric cancer Intravenoushttp://www.emdserono.com/en/research/Pipeline/rese
arch.html
avelumab EMD Serono Third line gastric cancer Intravenoushttp://www.emdserono.com/en/research/Pipeline/rese
arch.html
AZD6738 AstraZeneca Gastric cancer, in combination with lynparzahttps://www.astrazeneca.com/our-focus-
areas/oncology.html
binimetinib Array BioPharmaBRAF-mutant colorectal cancer in
combination with encorafenib and cetuximabOral
http://www.arraybiopharma.com/product-
pipeline/binimetinib/
buparlisib Novartis Gastroesophageal junction cancer Oralhttps://www.novartisoncology.com/about-us/our-
pipeline
Cometriq cabozantinib Exelixis Advanced hepatocellular cancer Oral http://www.exelixis.com/pipeline
Cotellic cobimetinibHoffmann-La
Roche
Third-line advanced or metastatic colorectal
cancer, in combination with TecentriqOral
http://www.roche.com/research_and_development/w
ho_we_are_how_we_work/pipeline.htm
codrituzumabHoffmann-La
RocheMetastatic liver cancer
http://www.roche.com/research_and_development/w
ho_we_are_how_we_work/pipeline.htm
durvalumab +
tremelimumabAstraZeneca Gastric cancer Intravenous
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
encorafenib Array BioPharmaBRAF-mutant colorectal cancer in
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Tecentriq atezolizumabHoffmann-La
Roche
1st-line cis-ineligible and 2nd-line metastatic
urothelial bladder cancerIntravenous
http://www.roche.com/research_and_development/w
ho_we_are_how_we_work/pipeline.htm
Tecentriq atezolizumabHoffmann-La
RocheRenal cell cancer, in combination with Avastin Intravenous
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Inlyta axitinib PfizerRenal cell carcinoma adjuvant, in combination
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Gynecological Cancer
Tecentriq atezolizumabHoffmann-La
RocheOvarian cancer, front-line treatment
http://www.roche.com/research_and_development/w
ho_we_are_how_we_work/pipeline.htm
avelumab EMD Serono Platinum resistant/refractory ovarian cancer Intravenoushttp://www.emdserono.com/en/research/Pipeline/rese
arch.html
avelumab EMD Serono First line ovarian cancer Intravenoushttp://www.emdserono.com/en/research/Pipeline/rese
arch.html
AZD1775 AstraZenecaOvarian cancer, in combination with
chemotherapy
https://www.astrazeneca.com/our-focus-
areas/oncology.html
Avastin bevacizumab Genentech First-line metastatic ovarian cancer Intravenous http://www.gene.com/medical-professionals/pipeline
Avastin bevacizumabHoffmann-La
RocheRelapsed platinum-sensitive ovarian cancer Intravenous
http://www.roche.com/research_and_development/w
ho_we_are_how_we_work/pipeline.htm
Cometriq cabozantinib Exelixis Endometrial cancer Oral
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Nimoral nimorazole Azanta A/S
First-line platinum-resistent head and neck
squamous cell carcinoma, versus
conventional radiation therapy
Oral http://www.azanta.com/pipeline.aspx
Nimoral nimorazole Azanta A/S
Head and neck squamous cell carcinoma,
second line re-irradiation, accelerated or
conventinal chemo-radiation therapy (CRT)
Oral http://www.azanta.com/pipeline.aspx
Nimoral nimorazole Azanta A/S
Head and neck squamous cell carcinoma,
first line accelerated chemo-radiation therapy
(CRT)
Oral http://www.azanta.com/pipeline.aspx
Ibrance palbociclib PfizerSquamous cell carcinoma of the head and
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Mylotarg Pfizer 1st Line Acute Myeloid Leukemia (Biologic)http://www.pfizer.com/sites/default/files/product-
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
avelumab EMD Serono Second line non-small cell lung cancer Intravenoushttp://www.emdserono.com/en/research/Pipeline/rese
arch.html
Avastin bevacizumab Genentech Adjuvant non-small cell lung cancer Intravenous http://www.gene.com/medical-professionals/pipeline
BI 1361849Boehringer
IngelheimNon-small cell lung cancer http://www.inoncology.com/trials/phaseII.html
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Rova-Trovalpituzumab
tesirineAbbVie Small cell lung cancer, third line Intravenous
http://www.abbvie.com/research-
innovation/pipeline.html
Rova-Trovalpituzumab
tesirineAbbVie Small cell lung cancer, first line Intravenous
https://www.abbvie.com/our-science/pipeline.html
tepotinib EMD Serono Non-small cell lung cancer Oralhttp://www.emdserono.com/en/research/Pipeline/rese
arch.html
veliparib AbbVie Squamous non-small cell lung cancer Oralhttp://www.abbvie.com/research-
innovation/pipeline.html
veliparib AbbVie Non-squamous non-small cell lung cancer Oralhttp://www.abbvie.com/research-
innovation/pipeline.html
Cancer Drug Pipeline Information for Patient Advocacy Groups
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Adcetrisbrentuximab
vedotinSeattle Genetics
Second-line Hodgkin lymphoma, in
combination with nivolumabIntravenous http://www.seattlegenetics.com/pipeline
Adcetrisbrentuximab
vedotinSeattle Genetics
Relapsed non-Hodgkin lymphoma, in
combination with nivolumabIntravenous http://www.seattlegenetics.com/pipeline
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Imbruvica ibrutinib Janssen
Treatment naive patients with mantle cell
lymphoma, in combination with
Bendamustine and Rituximab
Oral
http://files.shareholder.com/downloads/JNJ/24645
92300x0x674691/1423ebb6-9534-413e-9af6-
c0b1c429da15/JNJ_Pipeline.pdf
Imbruvica ibrutinib Janssen
Relapsed/refractory indolent non-Hodgkin's
lymphoma, in combination with
bendamustine and rituximab or R-CHOP
Oral
http://files.shareholder.com/downloads/JNJ/24645
92300x0x674691/1423ebb6-9534-413e-9af6-
c0b1c429da15/JNJ_Pipeline.pdf
Imbruvica ibrutinib Janssen
Newly diagnosed non-germinal centre B-cell
subtype of diffuse large B-cell lymphoma, in
combination with R-CHOP
Oral
http://files.shareholder.com/downloads/JNJ/24645
92300x0x674691/1423ebb6-9534-413e-9af6-
c0b1c429da15/JNJ_Pipeline.pdf
Imbruvica ibrutinib JanssenMarginal zone lymphoma in patients who
have received at least one prior therapyOral
http://files.shareholder.com/downloads/JNJ/24645
92300x0x674691/1423ebb6-9534-413e-9af6-
c0b1c429da15/JNJ_Pipeline.pdf
Imbruvica ibrutinib JanssenMarginal zone lymphoma in patients who
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Venclexta venetoclaxHoffmann-La
RocheFront-line diffuse large B-cell lymphoma Oral
http://www.roche.com/research_and_development/w
ho_we_are_how_we_work/pipeline.htm
Venclexta venetoclaxHoffmann-La
Roche
Relapsed/refractory follicular lymphoma, in
combination with rituximabOral
http://www.roche.com/research_and_development/w
ho_we_are_how_we_work/pipeline.htm
Venclexta venetoclaxHoffmann-La
RocheRelapsed or refractory multiple myeloma Oral
http://www.roche.com/research_and_development/w
ho_we_are_how_we_work/pipeline.htm
Cancer Drug Pipeline Information for Patient Advocacy Groups
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.
Brand Name Generic Name Manufacturer Indication Route of
Administration
Information Source
Cancer Drug Pipeline Information for Patient Advocacy Groups Please note: CCAN and CADTH do not represent or warrant that any of the drug products listed in the Cancer Drug Pipeline Information for Patient Advocacy Groups will be submitted
to the pCODR program. The use of this information is solely intended for informational purposes to assist patient advocacy groups to be more informed about the anticipated cancer
drug products or indications that are listed in the pipeline. Please be advised that the information contained in this document is not a comprehensive list. Please contact
[email protected] with any inquiries about the information contained in this document.